Carvacryl acetate

Carvacryl acetate 是一种口服有效且可通过血脑屏障的 TRPA1 受体激活剂和 Na+/K+-ATPase 激活剂,可调控 GABA 能信号通路,改变海马组织中 GABA 和谷氨酰胺水平,减少脂质过氧化和亚硝酸盐生成,清除羟自由基,并提升谷胱甘肽和抗氧化酶活性,同时可抑制 Haemonchus contortus 的幼虫孵化、发育、成虫运动能力和粪便虫卵数,并造成成虫结构损伤,因此可用于肠黏膜炎、胃肠道线虫感染、癫痫和神经退行性疾病的相关研究。
产品编号: MS-M28241 纯度: 99.80% CAS No.: 6380-28-5 分子式: C12H16O2 分子量: 192.25
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价

产品描述

Carvacryl acetate 是一种口服有效且可通过血脑屏障的 TRPA1 受体激活剂和 Na+/K+-ATPase 激活剂,可调控 GABA 能信号通路,改变海马组织中 GABA 和谷氨酰胺水平,减少脂质过氧化和亚硝酸盐生成,清除羟自由基,并提升谷胱甘肽和抗氧化酶活性,同时可抑制 Haemonchus contortus 的幼虫孵化、发育、成虫运动能力和粪便虫卵数,并造成成虫结构损伤,因此可用于肠黏膜炎、胃肠道线虫感染、癫痫和神经退行性疾病的相关研究。

生物实验数据

生物活性 Carvacryl acetate is an orally active TRPA1 receptor activator and Na+/K+-ATPase activator that crosses the blood-brain barrier, modulates GABAergic signaling pathways, alters GABA and glutamine levels in hippocampal tissue, reduces lipid peroxidation and nitrite production, scavenges hydroxyl radicals, and enhances glutathione and antioxidant enzyme activity, while also inhibiting larval hatching, development, adult motility, and fecal egg counts of Haemonchus contortus and causing structural damage to adult worms, and is therefore useful for research on intestinal mucositis, gastrointestinal nematode infections, epilepsy, and neurodegenerative diseases.
IC50 & Target

TRPA1

 

体外研究
(In Vitro)

Carvacryl acetate 可通过与 8 个氨基酸残基形成稳定相互作用,紧密结合 TRPA1 受体 (PDB ID: 3J9P),其抑制常数为 36.8 μM,结合能为-6.1 kcal/mol。
Carvacryl acetate (0.5-8 mg/mL;48 小时) 呈剂量依赖性抑制 Haemonchus contortus 的虫卵孵化,其 EC50 为 1.7 mg/mL,在 48 h 孵育后,8 mg/mL 浓度下的抑制率可达 89.3%。
Carvacryl acetate (0.125-2 mg/mL;6 小时) 可剂量依赖性地抑制 Haemonchus contortus 的幼虫发育,其 EC50 为 0.3 mg/mL,孵育 6 天后在 2 mg/mL 浓度下抑制率可达 100%。
Carvacryl acetate (25-200 μg/mL;6-24 小时) 呈剂量和时间依赖性地抑制 Haemonchus contortus 成虫的运动能力,在孵育 24 h 后,200 μg/mL 浓度下的抑制率达到 100%。
Carvacryl acetate (200 μg/mL;24 小时) 会诱导 Haemonchus contortus 雌成虫发生结构损伤,包括角质层和阴门皱襞起皱以及体被气泡形成。
Carvacryl acetate (0.9-7.2 μg/mL;30 分钟) 可强效抑制 AAPH 诱导的蛋黄匀浆中脂质过氧化,其 EC50 为 0.1785 μg/mL,且在浓度≥1.8 μg/mL 时表现出比 Trolox 更强的抑制活性。
Carvacryl acetate (0.9-7.2 μg/mL;1 小时) 可清除无细胞体系中由 SNP 产生的 NO,其 EC50 为 0.1940 μg/mL。
Carvacryl acetate (0.9-7.2 μg/mL;15 分钟) 可在无细胞体系中清除芬顿反应产生的羟自由基,其 EC50 为 0.1397 μg/mL,并呈现浓度依赖性抑制作用。

体内研究
(In Vivo)

Carvacryl acetate (25-150 mg/kg;腹腔注射;每天一次,连续八天) 对雌性 Swiss 小鼠中 Irinotecan (MS-O02109) 诱导的肠黏膜炎表现出强效的抗炎和抗氧化功效,其中 75 mg/kg 腹腔注射剂量可实现 100%存活率,并通过激活 TRPA1 受体将关键的组织学、炎症和氧化应激参数恢复至接近正常水平。
Carvacryl acetate (500-4000 mg/kg;口服;单次给药) 在雌性 Swiss albino 小鼠中表现出较低的急性口服毒性,其 LD50 为 1544.5 mg/kg。
Carvacryl acetate (250 mg/kg;口服;单次给药) 在单次口服 250 mg/kg 剂量后第 16 天,可使自然感染胃肠道线虫的绵羊粪便虫卵数减少 65.9%。
Carvacryl acetate (100 mg/kg;腹腔注射;单次给药;Pilocarpine 给药前 30 分钟) 对 Pilocarpine (MS-U99376) 诱导的小鼠癫痫发挥抗惊厥作用,可使癫痫发作率降低 60%、死亡率降低 40%,使癫痫发作潜伏期延长 340.55%,并通过 GABA 能介导的机制改善海马区酶类及 GABA 水平。
Carvacryl acetate (100 mg/kg;腹腔注射;单次给药;pentylenetetrazol 给药前 30 分钟) 对小鼠 pentylenetetrazol 诱导的癫痫具有抗惊厥作用,可分别使癫痫发作和死亡率降低 70%,使癫痫发作潜伏期延长 345.96%,并通过 GABA 能介导的机制改善海马酶和 GABA 水平。
Carvacryl acetate (100 mg/kg;腹腔注射;单次给药;Picrotoxin 给药前 30 分钟) 对 Picrotoxin (MS-F58453) 诱导的小鼠癫痫具有抗惊厥作用,可分别使癫痫发作率和死亡率降低 50%,使癫痫发作潜伏期延长 163.67%,并通过 GABA 能介导的机制改善海马区酶类和 GABA 水平。
Carvacryl acetate (100 mg/kg;腹腔注射;单次给药) 对健康小鼠的自发活动或运动协调性无影响。
Carvacryl acetate (25-100 mg/kg;腹腔注射;单次注射) 在小鼠海马体中表现出强效的体内抗氧化活性,与溶媒对照组相比,100 mg/kg 剂量可使 TBARS 水平降低 85%、亚硝酸盐含量降低 92%、GSH 水平升高 50%、过氧化氢酶活性升高 88%。

Animal Model: Swiss mice (female, 25-30 g, intestinal mucositis induced via intraperitoneal injection of Irinotecan 75 mg/kg on days 2-5 of an 8-day study)
Dosage: 25 mg/kg; 75 mg/kg; 150 mg/kg
Administration: i.p.; daily for 8 days
Result: Achieved 87.5% survival at 25 mg/kg dose.
Achieved 100% survival at 75 mg/kg dose.
Achieved 87.5% survival at 150 mg/kg dose.
Resulted in a body mass loss of 4.6 g over 7 days at 25 mg/kg dose.
Resulted in a body mass loss of 4.4 g over 7 days at 75 mg/kg dose.
Resulted in a body mass loss of 3.4 g over 7 days at 150 mg/kg dose.
Restored leucocyte count to 5710 leucocytes/mm3 at 75 mg/kg dose, reversing CPT-11-induced neutropenia.
Reduced bacterial load to levels comparable to DMSO-treated control mice at 75 mg/kg dose.
Reduced histological injury scores to 0-2 at 75 mg/kg dose, compared to 3-4 in CPT-11-treated mice.
Restored villi height to 185 μm and crypt depth to 86.5 μm at 75 mg/kg dose, reversing CPT-11-induced shortening.
Restored Na+/K+-ATPase activity to 2156 μmol Pi/mg protein/h at 75 mg/kg dose, reversing CPT-11-induced reduction.
Reduced myeloperoxidase (MPO) activity to 1.16 U MPO/mg tissue at 75 mg/kg dose.
Reduced pro-inflammatory cytokine levels to 148.4 pg/mL (IL-1β), 497.9 pg/mL (KC), and 46.24 pg/mL (TNF-α) at 75 mg/kg dose.
Reduced immunostained cells for NF-κB to 23.58 and COX-2 to 12.14 at 75 mg/kg dose.
Reduced malondialdehyde (MDA) to 111.8 nmol/mL and nitric oxide metabolites (NOx) to 0.24 μM at 75 mg/kg dose.
Increased glutathione (GSH) to 610.5 μg/mL and superoxide dismutase (SOD) to 5.04 U SOD/μg at 75 mg/kg dose.
Animal Model: Swiss albino (female, average weight 25 g)
Dosage: 500 mg/kg; 1000 mg/kg; 2000 mg/kg; 4000 mg/kg
Administration: p.o.; single dose
Result: Determined an LD10 of 566.7 mg/kg.
Determined an LD50 of 1544.5 mg/kg.
Showed no behavioral changes in treated mice during the 15-day observation period.
Animal Model: Sheep (both sexes, 6-16 months old, average weight 18 kg)
Dosage: 250 mg/kg
Administration: p.o.; single dose
Result: Reduced fecal egg counts by 35.4% at 8 days post-treatment.
Reduced fecal egg counts by 65.9% at 16 days post-treatment.
Shifted nematode larvae composition from 90% Haemonchus spp., 7% Trichostrongylus spp., 3% Oesophagostumum spp. pre-treatment to 43% Haemonchus spp., 51% Trichostrongylus spp., 6% Oesophagostumum spp. at 16 days post-treatment.
Animal Model: Swiss albino (male, 25-30 g, 2 months old, Pilocarpine-induced epilepsy)
Dosage: 100 mg/kg
Administration: i.p.; single dose; 30 minutes before Pilocarpine
Result: Reduced seizure incidence by 60% and mortality by 40% compared to Pilocarpine-only controls.
Increased latency to first seizure by 340.55% compared to Pilocarpine-only controls.
Increased hippocampal δ-ALA-D activity by 47.35% and Na+, K+-ATPase activity by 30.7% compared to Pilocarpine-only controls.
Increased hippocampal GABA levels by 78.25% compared to Pilocarpine-only controls.
Did not alter glutamate, aspartate, or glutamine levels relative to Pilocarpine-only controls.
Had effects reversed by flumazenil.
Animal Model: Swiss albino (male, 25-30 g, 2 months old, pentylenetetrazol-induced epilepsy)
Dosage: 100 mg/kg
Administration: i.p.; single dose; 30 minutes before pentylenetetrazol
Result: Reduced seizure incidence by 70% and mortality by 70% compared to pentylenetetrazol-only controls.
Increased latency to first seizure by 345.96% compared to pentylenetetrazol-only controls.
Increased hippocampal δ-ALA-D activity by 83.38% and Na+, K+-ATPase activity by 28% compared to pentylenetetrazol-only controls.
Increased hippocampal GABA levels by 51.43% compared to pentylenetetrazol-only controls.
Did not alter glutamate, aspartate, or glutamine levels relative to pentylenetetrazol-only controls.
Had effects reversed by flumazenil.
Animal Model: Swiss albino (male, 25-30 g, 2 months old, Picrotoxin-induced epilepsy)
Dosage: 100 mg/kg
Administration: i.p.; single dose; 30 minutes before Picrotoxin
Result: Reduced seizure incidence by 50% and mortality by 50% compared to Picrotoxin-only controls.
Increased latency to first seizure by 163.67% compared to Picrotoxin-only controls.
Increased hippocampal δ-ALA-D activity by 57.24% and Na+, K+-ATPase activity by 32.6% compared to Picrotoxin-only controls.
Increased hippocampal GABA levels by 103% and reduced glutamine levels by 42.8% compared to Picrotoxin-only controls.
Did not alter glutamate or aspartate levels relative to Picrotoxin-only controls.
Had effects reversed by flumazenil.
Animal Model: Swiss albino (male, 25-30 g, 2 months old)
Dosage: 100 mg/kg
Administration: i.p.; single dose
Result: Produced no significant change in spontaneous locomotor activity compared to vehicle controls.
Produced no significant change in motor coordination compared to vehicle controls.
Animal Model: Swiss albino (male, 2 months old, 25-30 g)
Dosage: 25 mg/kg; 50 mg/kg; 75 mg/kg; 100 mg/kg
Administration: i.p.; single injection
Result: Reduced hippocampal thiobarbituric acid reactive substances (TBARS) levels by 65%, 70%, 72%, and 85% respectively compared to vehicle (p < 0.0001), and by 33%, 43%, 48%, and 71% respectively compared to ascorbic acid 250 mg/kg (p < 0.0001).
Reduced hippocampal nitrite content by 78%, 82%, 85%, and 92% respectively compared to vehicle (p < 0.0001), and by 56%, 65%, 71%, and 85% respectively compared to ascorbic acid 250 mg/kg (p < 0.0001).
Increased hippocampal reduced glutathione (GSH) levels by 26%, 33%, 40%, and 50% respectively compared to vehicle (p < 0.05 for 25, 50, 75 mg/kg; p < 0.001 for 100 mg/kg).
Increased hippocampal glutathione peroxidase (GPx) activity by 49%, 52%, 71%, and 102% respectively compared to vehicle (p < 0.0001); the 75 mg/kg dose was superior to the 50 mg/kg dose (p < 0.001), and the 100 mg/kg dose was superior to the 75 mg/kg dose (p < 0.0001).
Increased hippocampal catalase activity by 57%, 63%, 57%, and 88% respectively compared to vehicle (p < 0.0001).
Did not significantly change hippocampal superoxide dismutase (SOD) activity at any tested dose compared to vehicle.
性状 液体(密度:0.994 g/cm3)
颜色 Colorless to light yellow

化学信息

分子量 192.25
分子式 C12H16O2
CAS No. 6380-28-5

储存&溶解度

储存方式
Pure form -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础